Stifel Nicolaus Forecasts Strong Price Appreciation for TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group (NASDAQ:TMDX) had its target price lifted by stock analysts at Stifel Nicolaus from $75.00 to $80.00 in a report released on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 9.26% from the stock’s current price.

TMDX has been the topic of a number of other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Canaccord Genuity Group dropped their price objective on TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, TD Cowen dropped their price objective on TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $134.50.

TransMedics Group Price Performance

NASDAQ TMDX opened at $73.22 on Thursday. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The company has a market capitalization of $2.53 billion, a PE ratio of 16.64 and a beta of 1.91. The firm’s 50 day moving average is $84.57 and its 200-day moving average is $113.51.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. During the same quarter last year, the business earned $0.70 earnings per share. TransMedics Group’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities research analysts anticipate that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $29,000. Optiver Holding B.V. raised its stake in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after acquiring an additional 191 shares during the period. North Star Investment Management Corp. bought a new stake in TransMedics Group in the 1st quarter valued at $30,000. Ascentis Independent Advisors bought a new stake in TransMedics Group in the 1st quarter valued at $30,000. Finally, Allworth Financial LP raised its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.